Centessa Pharmaceuticals plc (LON:0ACX)

Market Cap	3.15B +83.6%
Revenue (ttm)	11.16M +118.9%
Net Income	-180.55M
EPS	-1.35
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	690
Average Volume	740
Open	29.82
Previous Close	30.44
Day's Range	28.87 - 29.82
52-Week Range	9.86 - 30.54
Beta	1.55
RSI	56.99
Earnings Date	Apr 2, 2026

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatme...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Employees: 114
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ACX

Financial Performance

Financial numbers in USD